Ubiquitin-specific protease 7 (USP7) is a central regulator of multiple oncogenic pathways and is associated with tumor aggressiveness and poor prognosis across several cancer types. Researchers from Molecure SA characterized the preclinical profile of OAT-4828, a selective USP7 inhibitor with antiproliferative activity.
T-Curx GmbH has obtained clinical trial approval from the Swiss agency Swissmedic for the company’s nonviral lead CAR T program, TCX-001. The first-in-human phase I study will open in Switzerland, and a submission to the EMA will seek to expand the trial to sites in Germany. The study will enroll adults with relapsed or refractory acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL), including patients not eligible for stem cell transplantation.
Shenzhen Chipscreen Biosciences Co. Ltd. has divulged histone deacetylase (HDAC) inhibitors found to be potentially useful for the treatment of cancer.
Scientists from the Purdue Research Foundation have prepared and tested prostate-specific membrane antigen (PSMA)-targeting ligands covalently linked to the poly(ADP-ribose) polymerase (PARP) inhibitor niraparib through a releasable, reductively cleavable NADS linker.
Antengene Corp. Ltd. has obtained IND approval from China’s National Medical Products Administration (NMPA) for ATG-201 for the treatment of B-cell related autoimmune diseases.
Phoremost Ltd. has unveiled its lead program, PMC-001, a next-generation, small-molecule microtubule-targeting agent (MTA) for primary and secondary brain cancers. PMC-001 is a highly differentiated, orally bioavailable MTA.
Researchers from the University of Milan and collaborators reported the discovery and preclinical profile of a first-in-class covalent PFKFB3 inhibitor designed to achieve durable and selective suppression of tumor glycolysis while potentially improving tolerability compared with nonselective or reversible glycolysis inhibitors.
Pheon Therapeutics Ltd. has patented antibody-drug conjugates, comprising an antibody targeting CDCP1 covalently linked to a cytotoxic drug through a linker, that are potentially useful for the treatment of cancer.
Scientists from F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have identified bicyclic tetrahydrothiazepine derivatives acting as diacylglycerol kinase α (DGKA) and/or diacylglycerol kinase ζ (DGKZ) inhibitors reported to be potentially useful for the treatment of cancer.
Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. has divulged tyrosine-protein phosphatase non-receptor type 1 (PTPN1; PTP-1B) and/or PTPN2 inhibitors that are potentially useful for the treatment of cancer.
RSS
